Importantly, leukemia stem cells (LSCs) rapidly reduced before HSCs, which indicated that they were more sensitive to the Tmem30a deletion than HSCs and might suggest that Tmem30a was a potential target for the treatment of chronic myelocytic leukemia. The gene discussed is CDC50A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.